In Trial 6, adolescent patients with moderate‑to‑severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W following a 600 mg loading dose, while adolescents <60 kg received 200 mg Q2W following a 400 mg loading dose. The primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2‑point improvement.1,2
Efficacy Results of DUPIXENT
at Week 16 (FAS)
|Achieved clear or
(IGA 0 or 1)
aResponder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2‑points on a 0‑4 scale at Week 16 (primary efficacy outcome).
Baseline:IGA 4 (severe), BSA: 54%,
Week 16:IGA 1 (almost clear), BSA: 4%,
A clinical responder was defined as a patient achieving IGA 0 or 1and at least a 2‑point improvement from baseline1
BSA, body surface area.
Actual adolescent clinical trial patient treated with DUPIXENT. Individual results may vary.
Severe erythema and severe
Moderate erythema and moderate
Mild erythema and mild
Just perceptible erythema, and
just perceptible papulation/infiltration
No inflammatory signs of
Not an actual patient.